Clinical Scorecard: Correction to Figure 2A in the DROPROP Trial of Dexamethasone Eye Drops for Retinopathy of Prematurity
At a Glance
Category
Detail
Condition
Retinopathy of prematurity (ROP), including type 1 ROP
Key Mechanisms
Not described in the correction notice.
Target Population
Not specified in the correction notice.
Care Setting
Not specified in the correction notice.
Key Highlights
Figure 2A in the original DROPROP trial report contained incorrect bar heights.
The figure was corrected online.
The corrected incidence of type 1 ROP was 20% among dexamethasone recipients.
The corrected incidence of type 1 ROP was 38% among placebo recipients.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
The correction notice does not specify the trial population details.
The corrected type 1 ROP incidence was 20% with dexamethasone eye drops and 38% with placebo. The correction notice does not provide prescribing recommendations.
